XOMA (NASDAQ:XOMA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of XOMA (NASDAQ:XOMA) from a hold rating to a buy rating in a research note published on Saturday morning.

Several other equities analysts also recently weighed in on XOMA. HC Wainwright reissued a “buy” rating and set a $104.00 target price on shares of XOMA in a research report on Wednesday, May 28th. Benchmark started coverage on XOMA in a report on Thursday, April 17th. They set a “buy” rating and a $35.00 price objective for the company.

XOMA Stock Performance

NASDAQ XOMA opened at $24.27 on Friday. The company has a market cap of $290.44 million, a P/E ratio of -6.97 and a beta of 0.94. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The business’s 50 day moving average price is $24.02 and its 200-day moving average price is $24.52. XOMA has a fifty-two week low of $18.35 and a fifty-two week high of $35.00.

XOMA (NASDAQ:XOMA) last released its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.32. The firm had revenue of $15.91 million for the quarter, compared to the consensus estimate of $6.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. Sell-side analysts predict that XOMA will post -1.41 earnings per share for the current year.

Insider Activity at XOMA

In related news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the company’s stock in a transaction on Friday, May 16th. The stock was sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the completion of the sale, the insider now directly owns 1,267,545 shares in the company, valued at $34,350,469.50. This represents a 23.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Owen Hughes sold 25,637 shares of the company’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total value of $650,667.06. Following the sale, the chief executive officer now owns 62,701 shares of the company’s stock, valued at $1,591,351.38. This trade represents a 29.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders acquired a total of 29,312 shares of company stock worth $735,061 in the last quarter. 9.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Woodline Partners LP increased its holdings in shares of XOMA by 7.9% in the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after purchasing an additional 12,284 shares during the period. Stonepine Capital Management LLC grew its holdings in XOMA by 3.3% during the first quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company’s stock worth $2,587,000 after acquiring an additional 4,113 shares during the period. Nuveen LLC acquired a new stake in XOMA during the first quarter worth about $286,000. Deutsche Bank AG grew its holdings in XOMA by 5,087.9% during the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 6,309 shares during the period. Finally, CM Management LLC grew its holdings in XOMA by 16.4% during the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock worth $1,276,000 after acquiring an additional 9,000 shares during the period. 95.92% of the stock is owned by institutional investors and hedge funds.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.